New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus.
Summary withdrawn
TitrateLab removes an AI-written study summary when it states findings we cannot trace to the study's own record, or when the study falls outside the compounds we track. Read the original record through the link above.
amylin-agonist
glp-1-agonist
obesity
type-2-diabetes
weight-loss
glycemic-control
